Targeted drugs for advanced cancer move from specialist units to community setting

Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich,(1) shows that cutting-edge precision medicine is spreading from highly specialist cancer units to other healthcare facilities so more patients can benefit, wherever they are treated.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news